Status:
COMPLETED
A Study of LY3214996 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolab...
Eligibility Criteria
Inclusion
- Overtly health males
- Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
Exclusion
- Females
- Male participants sexually active with a pregnant partner
- Are currently enrolled in a clinical study or have participated, within the last 30 days, in a clinical study
- Have participated in a radiolabeled drug study within the previous 4 months
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
- Have a history of Gilbert's syndrome
- Have history or presence of psychiatric disorders
- Show evidence of human immunodeficiency virus (HIV) infection
- Show evidence of hepatitis C
- Show evidence of hepatitis B
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2019
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04033341
Start Date
August 1 2019
End Date
September 9 2019
Last Update
October 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Inc
Madison, Wisconsin, United States, 53704